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Abstract
TNF‐related apoptosis‐inducing ligand (TRAIL) induces apoptosis selectively in cancer
cells. For melanoma, the targeting of TRAIL signaling appears highly attractive,
due to pronounced TRAIL receptor expression in tumor tissue. However, mechanisms
of TRAIL resistance observed in melanoma cells may limit its clinical use. The Bcl‐2
family members are critical regulators of cell‐intrinsic apoptotic pathways. Thus, the
antiapoptotic Bcl‐2 protein myeloid cell leukemia 1 (Mcl‐1) is overexpressed in many
tumor types and was linked to chemotherapy resistance in melanoma. In this study,
we evaluated the involvement of antiapoptotic Bcl‐2 proteins (Bcl‐2, Bcl‐xL, Bcl‐w,
Mcl‐1, Bcl‐A1, and Bcl‐B) in TRAIL resistance. They were targeted by small interfering
RNA‐mediated silencing in TRAIL‐sensitive (A‐375, Mel‐HO) and in TRAIL‐resistant
melanoma cell lines (Mel‐2a, MeWo). This highlighted Mcl‐1 as the most efficient
target to overcome TRAIL resistance. In this context, we investigated the effects of
Mcl‐1‐targeting microRNAs as well as the Mcl‐1‐selective inhibitor S63845. Both
miR‐193b and S63845 resulted in significant enhancement of TRAIL‐induced
apoptosis, associated with decreased cell viability. Apoptosis induction was
mediated by caspase‐3 processing as well as by Bax and Bak activation, indicating
the critical involvement of intrinsic apoptosis pathways. These data may indicate
a high relevance of Mcl‐1 targeting also in melanoma therapy. Furthermore, the
data may suggest to consider the use of the tumor suppressor miR‐193b as a
strategy for countering TRAIL resistance in melanoma.
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1 | INTRODUCTION
Selective inhibitors for the mitogen‐activated protein (MAP) kinases
BRAF and MAP kinase‐ERK kinase, as well as immune checkpoint
modulators, have significantly improved melanoma therapy in recent
years, demonstrating the high potential of targeted strategies in
cancer.1‐3 Nevertheless, melanoma remains the major cause of skin
cancer‐related deaths.3 Thus, new ideas and strategies for further
improvement of melanoma therapy are still urgently needed. Most
anticancer therapies focus on two key hallmarks of cancer, either
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targeting excessive tumor cell proliferation or targeting induction of
apoptosis. Even immune‐modulating therapies finally aim at the
elimination of cancer cells by the induction of apoptosis.4,5 Two
major paths have been described for apoptosis induction, namely (a)
extrinsic pathways through death ligands such as TNF‐related
apoptosis‐inducing ligand (TRAIL) and (b) intrinsic, mitochondrial
pathways in course of cellular stress situations, for example, DNA
damage.6,7
TRAIL triggers apoptosis via the two agonistic death receptors
TRAIL‐R1/DR4 and TRAIL‐R2/DR5.8,9 Upon receptor binding, a
membrane‐bound, death‐inducing signaling complex is formed, where
initiator caspase‐8 and ‐10 are activated.10 In a caspase cascade,
effector caspases as caspase‐3 are further activated, which cleave a
large number of death substrates to finally execute apoptosis'
programs.11 Caspase‐3 is negatively regulated through the binding of
XIAP (chromosome X‐linked inhibitor of apoptosis protein).12
A particular advantage of TRAIL is selective apoptosis induction
in cancer cells, while normal tissue cells are largely spared.13,14 Al-
though melanoma cells have been shown to constitutively express
DR5, this does not guarantee TRAIL sensitivity, as roughly half of
melanoma cell lines reveal an intrinsic TRAIL resistance.15,16 To ad-
dress this limitation, different combination strategies have been
identified, which can sensitize melanoma cells for TRAIL‐induced
apoptosis. In this context, the control of mitochondrial apoptosis
pathways came into particular focus for explaining TRAIL resistance
in melanoma.17,18
Mitochondrial apoptosis pathways are decisively controlled by
the family of Bcl‐2 proteins, which share one to four distinct Bcl‐2
homology (BH) domains. Bcl‐2 proteins interact and control each
other by heterodimerization.19 In present models, proapoptotic,
multidomain proteins with three BH domains (Bax and Bak) are
bound and are antagonized by antiapoptotic Bcl‐2 proteins with four
BH domains (Bcl‐2, Bcl‐xL, myeloid cell leukemia 1 [Mcl‐1], Bcl‐w,
Bcl‐A1, and Bcl‐B). On top of this, proapoptotic BH3‐only proteins
(Bid, Bim, Bad, and several others), characterized by just the BH3 domain,
act as triggers in apoptosis through either binding and antagonizing the
antiapoptotic Bcl‐2 proteins or through directly activating Bax. BH3‐only
proteins themselves may be activated by several stimuli, as in particular
by cellular stress situations.20
Activation of Bax and Bak is associated with permeabilization of
the outer mitochondrial membrane and the release of mitochondrial
proteins, such as cytochrome c and Smac (second mitochondrial ac-
tivator of caspases). While cytochrome c promotes initiator caspase‐
9 activation via formation of the apoptosome, Smac inhibits the
caspase‐3 antagonist XIAP.21‐23
Expression of antiapoptotic Bcl‐2 proteins provides a basic me-
chanism to allow survival of normal cells and on the other hand, may
prevent apoptosis induction in malignant cells.24
Mcl‐1 appears of particular importance for the survival of dif-
ferent cell lineages during embryonic development, for example,
hematopoietic and neuronal cells.25,26 Its decisive role is also un-
derlined by embryonic lethality of Mcl‐1 knockout mice.27 In recent
years, the oncogenic activity of Mcl‐1 received particular
attention,28 which is indicated by the frequent genomic amplifica-
tion of Mcl‐1 in about 40% of tumors of different origin.29 Increased
Mcl‐1 protein levels were correlated to chemotherapy resistance of
leukemia as well as solid tumors as of the stomach, pancreas, and
bile duct.30,31
Besides transcription factors, gene expression is critically regu-
lated by small noncoding microRNAs (miRNAs) by the targeting
of complementary sequences on messenger RNA (mRNA). Some
miRNAs function as tumor suppressors through the downregulation
of antiapoptotic or oncogenic proteins, while others may be oncogenic
themselves through the downregulation of tumor suppressors. In the
context of Mcl‐1 regulation, miR‐339‐3p, and miR‐193b were de-
scribed as tumor suppressors in melanoma.32,33 On the contrary,
upregulated Mcl‐1 was associated with downregulation of miRNA‐32
in melanoma.34
In the present study, we investigated the effects of knockdown
of antiapoptotic Bcl‐2 proteins with regard to the sensitization of
melanoma cells for TRAIL‐induced apoptosis. This highlighted the
particular role of Mcl‐1. Thus, we further investigated and com-
pared different Mcl‐1 targeting strategies as the selective inhibitor
S63845, miR‐193b, and miR‐339‐3p to overcome TRAIL resistance
in melanoma cells.
2 | MATERIALS AND METHODS
2.1 | Cell culture
Origin of human melanoma cell lines used in this study (A‐375, SK‐
Mel‐13, SK‐Mel‐19, SK‐Mel‐23, Mel‐HO, JPC‐298, Mel‐2a, Mel‐JuSo,
and MeWo) has been described previously.35 Cells were cultivated
at 37°C, 5% CO2 in dulbecco’s modified eagle’s medium (DMEM)
(4.5 g/L glucose; Gibco, Invitrogen, Karlsruhe, Germany), supple-
mented with 10% fetal calf serum (FCS) and antibiotics (Biochrom,
Berlin, Germany).
For the different assays, melanoma cells were seeded in flat‐
bottom 24‐well plates at a density of 75.000 to 120.000 cells/well,
according to the growth performance of the cell lines. Single treat-
ments started at 48 hours after seeding (cell confluence at 50%‐70%).
Treatments of 100 ng/mL KillerTRAIL (AG‐40T; Adipogen, San Diego)
or 5 µM of the selective Mcl‐1 inhibitor S63845 (CAS# 1799633‐27‐4;
Abmole Bioscience Inc, Houston, TX) were usually applied for 24 hours,
when not stated differently.
Combination treatments with small interfering RNA (siRNA) and
miRNA, respectively, started early after seeding. Thus, 10 pmol
siRNA/miRNA and 1.5 µL Lipofectamine RNAiMAX (Thermo Fisher
Scientific, Waltham, MA) were diluted in 100 µL Opti‐MEM medium
(Invitrogen, Carlsbad, CA), which was given to freshly seeded cells.
After 24 hours, transfection medium was replaced by a fresh growth
medium (DMEM with 5% FCS, w/o antibiotics) and incubated for an
additional 24 hours. After this procedure (48 hours), cells received
additional treatments, for example, TRAIL and S63845 (usually for
another 24 hours).
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2.2 | Cell transfection with siRNA or miRNA
Transient reverse cell transfection with siRNA or miRNA was per-
formed with Lipofectamine RNAiMAX (Thermo Fisher Scientific) ac-
cording to the manufacturer´s protocol. An amount of 10 pmol
siRNA/miRNA and 1.5 µL Lipofectamine was given to 500 µL cell
suspension seeded in 24‐wells. The following siRNAs from Santa
Cruz Biotech (Dallas, TX): were applied: Bcl‐2 (sc‐61899), Bcl‐xL
(sc‐43630), Bcl‐w (sc‐37293), Mcl‐1 (sc‐35877), Bcl‐A1 (sc‐37285),
and Bcl‐B (sc‐90043) as well as a scrambled control (sc‐37007).
The following miRNAs were applied: miR‐339‐3p (hsa‐miR‐339‐3p:
HMI0497, Merck, Darmstadt, Germany) and miR‐193b (hsa‐miR‐193:
AM17100, Thermo Fisher Scientific, Life Technologies, Darmstadt,
Germany).
2.3 | Determination of apoptosis
For quantification of apoptosis, cell cycle analyses were performed.36
Cells harvested by trypsinisation were lysed in hypotonic buffer, and
isolated nuclei were stained for 1 hour with 40 µg/mL propidium
iodide (Sigma‐Aldrich, Taufkirchen, Germany). Cells in G1, G2, and
S‐phase, as well as sub‐G1 cells, were quantified by flow cytometry
(FL3A) with a FACS Calibur (BD Bioscience, Bedford, MA). Due to the
washing out of small DNA fragments, nuclei with less DNA than G1
(sub‐G1) correspond to apoptotic cells with fragmented DNA.
2.4 | Determination of cell viability and
mitochondrial membrane potential
Cell viability was determined by staining cells with calcein‐AM
(PromoCell, Heidelberg, Germany), which is converted in viable cells
to green‐fluorescent calcein by intracellular esterases. Cells, grown
and treated in 24‐well plates, were harvested by trypsinization and
stained with 0.5 µM calcein‐AM at 37°C for 1 hour. Labeled cells
were washed with phosphate‐buffered saline (PBS) and measured by
flow cytometry (FL2H).
Mitochondrial membrane potential (MMP) (Δψm) was de-
termined by staining cells with the fluorescent dye TMRM+ (Tetra-
methylrhodamine methyl ester perchlorate; Sigma‐Aldrich). Cells
grown in 24‐well plates and harvested by trypsinization were stained
for 20minutes at 37°C with 1 µM TMRM+. After two‐times washing
with PBS, cells were measured by flow cytometry (FL2H).
2.5 | Bax and Bak activation assays
For analysis of Bax/Bak conformational changes related to protein
activation, cells were stained with primary antibodies specific for the
Bax N‐terminal domain (Bax‐NT; rabbit; #06‐499; Merck Millipore,
Darmstadt, Germany) and for the Bak N‐terminal domain (Bak‐NT;
rabbit; #06‐536; Merck Millipore, Darmstadt, Germany),
respectively. Cells were harvested by trypsinisation and fixed for
30minutes at 4°C with 0.5% paraformaldehyde in PBS. Then, they
were incubated for 1 hour at 4°C in PBS/1% FCS containing Bax/Bak‐NT
antibodies (1:100) and 0.1% saponine for cell permeabilization.
Staining was proceeded by incubation for 1 hour at 4°C in the dark
using a goat anti‐rabbit secondary antibody (immunoglobulin G
[H + L]‐FITC; Jackson Immuno Research, West Grove, PA). After
washing and resuspension in PBS, cells were measured by flow
cytometry (FL1H).
2.6 | Western blotting
For preparing total protein extracts, cells were trypsinized, washed
with PBS and lysed in 150mM NaCl, 1% NP‐40 and 50mM Tris
(pH 8.0). To guaranty equal loading of samples in protein gels, con-
centrations of protein extracts were conscientiously determined in
triplicate determinations by Pierce Bicinchoninic acid protein assay
(Thermo Fisher Scientific). Western blotting on nitrocellulose mem-
branes was performed as described previously.35 Primary antibodies
were purchased from Cell Signaling (Danvers, MA): Cleaved caspase‐
3 (rabbit, 1:1000; #9661); caspase‐8 (mouse, 1:1000; #9746); cleaved
caspase‐9 (rabbit, 1:1000; #2002); Bcl‐xL (rabbit, 1:1000; #2762);
Mcl‐1 (rabbit, 1:1000; #4572); Bcl‐2 (rabbit, 1:1000; #2872); Bcl‐w
(rabbit, 1:1000; #2724) and glyceraldehyde 3‐phosphate dehy-
drogenase (GAPDH) (rabbit, 1:1000; #2118). Cells were finally
stained with secondary antibodies for 1 hour at room temperature,
using peroxidase‐labeled goat anti‐rabbit or goat anti‐mouse (dilution
of 1:5000; DakoPerkin Elmer, Waltham, MA). Proteins were detected
using Immobilon Western Chemiluminiscent HRP Substrate (Sigma‐
Aldrich, St Louis, MO) and visualized by Fusion FX Image analyzer.
2.7 | Real‐time polymerase chain reaction
To quantify the expression levels of Bcl‐A1 and Bcl‐B mRNAs, a
quantitative real‐time polymerase chain reaction (PCR) was used
(qTower; Analytik Jena, Jena, Germany). Total cellular RNA was
isolated with TRIzol lysis reagent (Thermo Fischer Scientific). For
reverse transcription, the First Strand complementary DNA Synth-
esis Kit of Thermo Fisher Scientific was applied. Real‐time PCR am-
plification for Bcl‐A1 and Bcl‐B was performed with the primers
given below using 2× PCR MasterMix (Thermo Fisher Scientific). For
normalization, a standard curve for GAPDH was used. Primers: Bcl‐
A1(FW), 5´‐GATAAGGCAAAACGGAGGCTGG‐3´; Bcl‐A1(Rev), 5´‐CT
CTTCTTGTGGGCCACTGAC‐3´; Bcl‐B(FW): 5´‐GGACACCGGGAC
ACGG‐3´; Bcl‐B(Rev): 5´‐GGGGGTCCTGAAGAAGTGAC‐3´.
2.8 | Statistical analyses
Assays were done in triplicate determinations, and at least two in-
dependent experiments were performed. For apoptosis and cell
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viability assays, depicted mean values and standard deviations were
calculated by enclosing all individual values of the independent ex-
periments. For MMP, Bax, and Bak assays, the mean values of re-
presentative experiments are shown. Statistical significance was
proven by the ANOVA test (two‐way, multiple comparisons), using
generally all obtained values of the independent experiments.
P values of less than .05 were considered statistically significant.
Depicted Western blot data were verified by at least two independent
series of cellular extracts.
3 | RESULTS
3.1 | Efficient knockdown of antiapoptotic Bcl‐2
proteins in melanoma cell lines by siRNA
To address the significance of antiapoptotic Bcl‐2 proteins in mela-
noma, expression of Bcl‐2, Bcl‐xL, Mcl‐1, and Bcl‐w was analyzed by
immunoblotting in a panel of nine representative melanoma cell lines
(A‐375, JPC‐298, Mel‐2a, Mel‐HO, MeWo, Mel‐JuSo, SK‐Mel‐13, SK‐
Mel‐19, and SK‐Mel‐23) (Figure 1A). Protein expression of anti-
apoptotic Bcl‐2 proteins Bcl‐A1 and Bcl‐B could not be determined
by commercial antibodies, due to low sensitivity (data not shown), as
also reported elsewhere.37,38 Consistently high expression was found
for Bcl‐xL, Bcl‐w, and Mcl‐1, whereas Bcl‐2 showed stronger variation,
with only weak expression in A‐375 and Mel‐JuSo (Figure 1A).
For investigating the role of antiapoptotic Bcl‐2 proteins in
TRAIL sensitivity of melanoma cells, protocols were established for
efficient knockdown by RNA interference. The established protocol
for siRNA transfection resulted in high knockdown efficiency at the
protein level, as demonstrated for Bcl‐xL, Mcl‐1, and Bcl‐w in Mel‐HO
and A‐375 as well as for Bcl‐2 in Mel‐HO (Figure 1B). Nonspecific off‐
target effects of siRNA transfection on Bcl‐2 protein expression were
largely excluded by transfection with a nonspecific siRNA (OffT). To
largely exclude also nonspecific effects of a given siRNA on other Bcl‐2
proteins, the expression levels of Bcl‐xL, Mcl‐1, Bcl‐2, and Bcl‐w were
determined after all siRNA treatments. Nontarget effects on other
Bcl‐2 proteins were less pronounced and mostly within the limits of
variation (Figure 1B).
As no suitable antibodies could be found for Bcl‐A1 and Bcl‐B,
we demonstrated the efficiency of their siRNA silencing in cell line
A‐375 at the mRNA level, using real‐time PCR. Thus, specific
knockdown by siRNAs resulted in a reduction of Bcl‐A1 mRNA levels
to 16% and 17%, respectively, as shown in two independent ex-
periments. Similarly, Bcl‐B mRNA was downregulated to 33% and
27%, respectively (Figure 1C).
3.2 | Sensitization of melanoma cells for TRAIL by
Mcl‐1 knockdown
To evaluate the significance of antiapoptotic Bcl‐2 proteins for cell
survival and TRAIL sensitivity of melanoma cells, Bcl‐2 proteins were
downregulated by six different siRNAs in TRAIL‐sensitive (A‐375 and
Mel‐HO) and in TRAIL‐resistant melanoma cell lines (MeWo and Mel‐
2a). Cells received TRAIL at 48 hours after the starting of siRNA
treatment, and effects on apoptosis (Figure 2) and on cell viability
(Figure 3) were analyzed after another 24 hours. TRAIL‐sensitive cell
lines responded to TRAIL with 21% (A‐375) and 11% apoptosis
(Mel‐HO), respectively. This effect was strongly enhanced by siMcl‐1,
resulting in 42% (A‐375) and 31% apoptosis (Mel‐HO). Resistant cell
lines (MeWo and Mel‐2a) showed no apoptotic response to TRAIL
(<6%). However, TRAIL‐induced apoptosis was significantly enhanced
by Mcl‐1 knockdown resulting in apoptosis values of 22% (MeWo)
and 20% (Mel‐2a), respectively. In contrast, combinations of TRAIL
with the other siRNAs were generally less effective for the induction
of apoptosis, and single treatments with siRNAs remained below 12%
(Figure 2).
The effects at the level of cell viability were largely in parallel.
Thus in A‐375 and Mel‐HO, TRAIL‐induced loss of cell viability was
enhanced by Mcl‐1 knockdown, leaving 39% and 28% viable cells,
respectively. In MeWo and Mel‐2a, the week effects of TRAIL on cell
viability were strongly enhanced, resulting in remaining viable cells of
only 57% (MeWo) and 35% (Mel‐2a). Again, other treatments were
less effective (Figure 3). Thus in four representative melanoma cell
lines, Mcl‐1 targeting turned out as the most promising strategy for
enhancing TRAIL sensitivity and for overcoming TRAIL resistance.
3.3 | Activation of mitochondrial apoptosis
pathways by TRAIL and Mcl‐1 knockdown
For better understanding, the pathways mediating enhanced TRAIL
sensitivity, activation of extrinsic initiator caspase‐8, intrinsic in-
itiator caspase‐9, and the predominant effector caspase‐3 were in-
vestigated by Western blotting in TRAIL‐sensitive A‐375 and in
resistant MeWo and Mel‐2a. In A‐375, TRAIL alone already resulted
in strong activation of the caspase cascade, seen by cleavage pro-
ducts of caspase‐9 (35 kDa), caspase‐8 (43, 41, and 18 kDa) and
caspase‐3 (21, 19, and 17 kDa) (Figure 4A). In contrast, almost no
caspase processing was seen in resistant MeWo and Mel‐2a in re-
sponse to TRAIL alone. In particular, no mature 17 kDa caspase‐3
cleavage product appeared (Figure 4B).
Mcl‐1 knockdown alone had some effect on caspase‐3 in the cell
lines as seen by the slightly enhanced 17 kDa product. This came
along with some processing of caspase‐9 in A‐375 and MeWo
(35 kDa) as well as some processing of caspase‐8 in Mel‐2a (18 kDa).
Strong activation of the caspase cascade as indicated by high ex-
pression of caspase‐3 cleavage products was seen in MeWo and
Mel‐2a under combination treatment (siMcl‐1 + TRAIL). In A‐375, the
effects of combination treatment were visible by a higher ratio of
caspase‐3 mature product (17 kDa) vs intermediate cleavage pro-
ducts of 19 and 21 kDa (Figure 4A). The finding of caspase‐8 acti-
vation in combinations may be at least partly explained by a positive
feedback loop leading from activated caspase‐3 up to caspase‐8, as
described earlier.39,40
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Loss of MMP, as an indicator of mitochondrial pathway acti-
vation, was investigated in A‐375, MeWo, and Mel‐2a at 72 hours
post‐siRNA transfection (TRAIL treatment for the last 24 hours).
Significant loss of MMP in course of TRAIL was seen in A‐375 (80%),
whereas MeWo and Mel‐2a were not responsive. Knockdown of
Mcl‐1 alone significantly decreased MMP in all three cell lines re-
sulting in 30% to 47% cells with low MMP. This effect was strongly
enhanced by combination treatment resulting in 96%, 51%, and 87%
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cells with low MMP in A‐375, MeWo, and Mel‐2a, respectively
(Figure 4B).
The proapoptotic effectors Bax and Bak critically control in-
trinsic apoptosis pathways. Activation of both proteins was de-
termined due to characteristic conformational changes monitored by
Bax‐NT (N‐terminus) and Bak‐NT antibodies, respectively. Significant
activation of both Bax and Bak was seen in A‐375 and MeWo as a
result of Mcl‐1 knockdown, as compared to Off‐target controls. Thus
in A‐375, Bax and Bak were activated 51% and 38% of cells; in
MeWo, 71% and 45% of cells showed activation of Bax and Bak,
respectively. Bax and Bak activation were further enhanced in A‐375
in the combination with TRAIL (71%/75%), whereas TRAIL remained
without additional effect in MeWo (Figure 4C,D). The fact that TRAIL
remained without effect on Bax/Bak activation in TRAIL‐resistant cell
line MeWo may be at least partly explained by previous findings
showing a strong relation of TRAIL resistance and lacking Bax
activation in melanoma cells.17,41
These data demonstrate that although the Mcl‐1 knockdown did
not efficiently induce apoptosis by itself, it preactivated mitochon-
drial apoptosis pathways, thus opening a “mitochondrial gate.” This
was then used by TRAIL for enhanced apoptosis induction.
3.4 | Mcl‐1 targeting by the Mcl‐1 inhibitor S63845
and by miRNAs
The role of Mcl‐1 in TRAIL resistance was further investigated in
the TRAIL‐resistant cell line MeWo by the novel BH3 mimetic and
specific Mcl‐1 antagonist S63845. When applied alone, S63845
resulted in 15% apoptosis induction and reduction of viable cells to
60%. The proapoptotic Bcl‐2 proteins Bax and Bak were strongly
activated by S63845 (44%). In combination with TRAIL, apoptosis
was strongly enhanced (42%) and cell viability was further de-
creased (15% remaining viable cells), while Bax and Bak activation
were not further affected in MeWo cells by additional TRAIL
(Figure 5A).
To evaluate alternative strategies for Mcl‐1 targeting, miR‐193b
and miR‐339‐3p, reported to downregulate Mcl‐1 expression, were
applied in MeWo cells and were compared to siMcl‐1. Comparable to
the effects of siMcl‐1, miR‐193b enhanced TRAIL‐induced apoptosis
by 4‐fold (15%, Figure 5B) and further decreased cell viability (53%
remaining viable cells, Figure 5C), as compared to the off‐target
controls. The effects of miR‐339‐3p showed a similar tendency but
were less pronounced. Clearly indicating the activation of mi-
tochondrial apoptosis pathways, miR‐193b alone significantly acti-
vated Bax (64%, Figure 5D) and Bak (52%, Figure 5E), comparable to
siMcl‐1 effects. In conclusion, the targeting of Mcl‐1 appeared as a
highly promising strategy to enhance the antineoplastic effects of
TRAIL, which may finally pave the way for therapeutic approaches.
The activated pathways were generally based on the activation of
Bax and Bak, underlining their particular roles in TRAIL‐induced
apoptosis in melanoma cells.
4 | DISCUSSION
Despite the development of new therapeutic approaches for meta-
static melanoma, survival prognosis is still limited, particularly due to
acquired therapy resistance.3 New ideas and additional strategies
may help to finally defeat this deadly disease. Apoptosis resistance
represents a critical hallmark in cancer,4 and the targeting of apop-
tosis pathways, for example, by the death ligand TRAIL, appears as a
promising antitumor strategy.18 The particular advantage of TRAIL is
based on its capability to selectively induce apoptosis in cancer cells,
while normal cells are largely spared.13,14
TRAIL agonists have proven good tolerability and safety profiles
in clinical trials, however, an additional clinical benefit, when TRAIL
was applied in combination therapies, so far remained on a low level.
For example, in B‐cell lymphoma patients treated with recombinant
TRAIL (dulanermin) in combination with rituximab (phase I) as well as
in nonsmall‐cell lung cancer patients treated with dulanermin in
combination with paclitaxel, carboplatin, and bevacizumab (phase II),
positive combination effects of TRAIL were reported only within the
first 6 months.42,43 Comparable results were obtained in a phase III
trial for advanced nonsmall‐cell lung cancer patients treated with
dulanermin in combinations with vinorelbine and cisplatin. Also here,
the early improvement of progression‐free survival seen for the
combination, vanished after 12 months.44
Lack of sustained TRAIL efficacy can be attributed to resistance
mechanisms, as reported in different cancer cells, for example, of the
F IGURE 1 Efficient knockdown of antiapoptotic Bcl‐2 proteins by siRNA. A, Expression of Bcl‐2, Bcl‐xL, Bcl‐w, and Mcl‐1 was determined by
Western blot analysis in nine human melanoma cell lines (A‐375, JPC‐298, Mel‐HO, MeWo, Mel‐JuSo, SK‐Mel‐13, SK‐Mel‐19, and SK‐Mel‐23).
Equal protein amounts (30 µg) were loaded in each lane, as proven by Ponceau staining and GAPDH, used as a loading control. Molecular
weights (in kDa), as determined by a protein standard, are given on the right side. Three independent series of protein extracts revealed
comparable results. B, Melanoma cell lines Mel‐HO and A‐375 and were transfected with each 10 pmol of siRNA against Bcl‐xL, Mcl‐1, Bcl‐2,
Bcl‐w, Bcl‐A1, and Bcl‐B or scrambled control (OffT), as indicated. Proteins were harvested at 48 hours posttransfection for analysis of Bcl‐2,
Bcl‐xL, Bcl‐w, and Mcl‐1 expression by Western blotting. Equal protein amounts (30 µg) were loaded in each lane as proven by Ponceau staining
and GAPDH, used as a loading control. Some variations seen here for the GAPDH signals may result from technical challenges in Western
blotting. But two independent series of protein extracts revealed highly similar results. C, Results of real‐time RT‐PCR determined in cell line
A‐375 for Bcl‐A1 (left) and Bcl‐B mRNA expression (right) are shown. The values of siRNA‐treated cells (siBcl‐A1, siBcl‐B) vs nontreated controls (Ctr,
set to 100%) are shown in two independent experiments (Exp 01/02). GAPDH, Glyceraldehyde 3‐phosphate dehydrogenase; Mcl, myeloid cell
leukemia; mRNA, messenger RNA; siRNA, small interfering RNA
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breast, colon, and ovary45,46 as well as of melanoma.47,48 In the
present study, consistent TRAIL resistance in melanoma cells is re-
presented by the cell lines MeWo and Mel‐2a, while TRAIL‐sensitive
cell lines (A‐375, Mel‐HO) may still develop inducible TRAIL
resistance.47 Countering TRAIL resistance mechanisms represents a
basic condition for the development of efficient TRAIL‐based clinical
approaches.
Multiple strategies have been tested in melanoma cells for
overcoming TRAIL resistance.17 These have revealed an insufficient
caspase cascade via caspase‐8/caspase‐3 as well as the requirement
of the mitochondrial amplification loop. The level of Bcl‐2 proteins
thus represents a highly critical step in the control of TRAIL sensi-
tivity.17,41,49,50 Upregulation of antiapoptotic Bcl‐2 proteins is a fre-
quent issue in cancer, which was also associated with TRAIL
resistance, for example, in pancreatic carcinoma and prostate cancer
cells.51‐53 TRAIL‐induced apoptosis in melanoma cells was particu-
larly correlated with Bax activation and was abrogated by Bcl‐2
overexpression.17,54 Thus, the targeting of antiapoptotic Bcl‐2 pro-
teins represents a promising strategy to sensitize melanoma cells for
TRAIL. This approach was further investigated here.
F IGURE 2 Sensitization for TRAIL‐induced apoptosis by Bcl‐2 protein knockdown. Effects of Bcl‐2 protein knockdown by siRNA on
TRAIL‐induced apoptosis were determined in TRAIL‐sensitive cell lines A‐375 and Mel‐HO as well as in the TRAIL‐resistant cell lines MeWo and
Mel‐2a. Assays were performed at 72 hours after the transfection of indicated siRNAs and at 24 hours after TRAIL treatment (100 ng/mL).
Apoptosis was determined by PI staining and flow cytometry (cell cycle analysis). Cell cycle phases (G1, G2, and the S‐phase) are indicated in
overlays given below; apoptotic cells correspond to weakly PI‐stained cells (sub‐G1 cells). Indicated mean values and SDs correspond to all
individual values of at least two independent experiments (each one with triplicates, at least six independent values). Statistical significance is
indicated for the comparison of the combinations vs TRAIL treatment alone (*P < .05, ANOVA, two‐way, multiple comparisons). ANOVA, analysis
of variance; SD, standard deviation; siRNA, small interfering RNA; TRAIL, TNF‐related apoptosis‐inducing ligand
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The particular roles of six antiapoptotic Bcl‐2 proteins (Bcl‐2,
Bcl‐xL, Mcl‐1, Bcl‐w, Bcl‐A1, Bcl‐B) have been acknowledged in
models explaining the mutual regulation of Bcl‐2 proteins.19 A major
goal of the present study was to evaluate their particular contribu-
tion to the regulation of TRAIL sensitivity in melanoma cells. The
established siRNA strategies mediated high efficiency and largely
specific effects, as verified by Western blotting. Some improvement
of the TRAIL effects was seen upon the downregulation of several
antiapoptotic Bcl‐2 proteins in different melanoma cell lines. How-
ever, in terms of apoptosis induction and loss of cell viability,
knockdown of Mcl‐1 turned out as the most efficient strategy, which
was effective in all four melanoma cell lines, investigated.
The Mcl‐1 gene was reported as amplified in different human cancer
types, also in melanoma, and high Mcl‐1 expression has often been as-
sociated with therapy resistance.28,29,55 A particular significance of Mcl‐1
for melanoma cell survival was also demonstrated when Mcl‐1 and
Bcl‐A1 knockdown were combined with chemotherapy.38,56
Addressing the mechanisms, by which Mcl‐1 knockdown en-
hanced TRAIL‐induced apoptosis in melanoma cells, activation of the
caspase cascade and increased loss of MMP was shown. Of particular
F IGURE 3 Loss of cell viability by combined TRAIL and Bcl‐2 protein knockdown. Effects of Bcl‐2 protein knockdown by siRNA on TRAIL‐
induced loss of cell viability were determined in TRAIL‐sensitive cell lines A‐375 and Mel‐HO as well as in the TRAIL‐resistant cell lines MeWo
and Mel‐2a. Assays were performed at 72 hours after the transfection of indicated siRNAs and at 24 hours after TRAIL treatment (100 ng/mL).
Cell viability was determined by calcein‐AM staining and flow cytometry; viable and nonviable cell populations are indicated in the overlays
given below. Indicated mean values and SDs correspond to all individual values of at least two independent experiments (each one with
triplicates, at least six independent values). Statistical significance is indicated for the comparison of the combinations vs TRAIL treatment alone
(*P < .05, ANOVA, two‐way, multiple comparisons). ANOVA, analysis of variance; SD, standard deviation; siRNA, small interfering RNA; TRAIL,
TNF‐related apoptosis‐inducing ligand
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note, the proapoptotic Bcl‐2 proteins Bax and Bak were consistently
activated in course of Mcl‐1 knockdown, indicating the dominant role
of Mcl‐1 in suppressing the activity of these important proapoptotic
agonists. We already showed that Bax serves as a master regulator of
TRAIL‐induced apoptosis in melanoma cells.17,18 On the other hand,
apoptosis in melanoma cells can also be mediated by Bak pathways,
as shown for Bcl‐xS‐induced apoptosis.57 Bak has been described as a
particular target of Mcl‐1.58,59
Antiapoptotic Bcl‐2 proteins may be antagonized by BH3 mi-
metics, which mimic the activity of proapoptotic BH3‐only proteins.
For preparing clinical applications, several BH3 mimetics have been
developed, for example, ABT‐199 (venetoclax) directed against Bcl‐2;
ABT‐263 (navitoclax) directed against Bcl‐2 and Bcl‐xL as well as
ABT‐737 directed against Bcl‐2, Bcl‐xL, and Bcl‐w. Monotherapy with
ABT‐199 resulted in improved overall survival of multiple myeloma
patients.60,61 However, patients with advanced solid tumors fre-
quently did not profit, for example, as reported for the combination
of ABT‐263 and the EGFR inhibitor erlotinib.60,61 In preclinical
studies, BH3 mimetics, in general, have shown less efficiency in
melanoma as compared to hematological cancers.62
Several previous BH3 mimetics did not affect Mcl‐1, which may
at least partly explain their insufficiency in melanoma. In the mean-
time, also Mcl‐1‐specific BH3 mimetics have been established
(S63845, AMG‐176, AMG‐397, and AZD‐599), which are planned for
clinical trials in patients with hematological malignancies.63 For
S63845, antitumor effects and low toxicity have been reported in
preclinical studies of multiple myeloma and leukemia. Most melano-
ma cells, however, showed pronounced resistance to S63845 when it
was applied alone.64 Also melanoma cell line MeWo, as shown here,
was almost not responsive to S63845 in terms of apoptosis induction
and loss of cell viability. However, MeWo cells showed strong acti-
vation of Bax and Bak in response to S63845, thus suggesting that a
proapoptotic gate was opened. This resulted in sensitization for
TRAIL‐induced apoptosis. S63845 has shown also positive effects in
melanoma cells when combined with other BH3 mimetics or the
proteasome inhibitor bortezomib.62
F IGURE 4 Apoptosis mechanisms in response to Mcl‐1 knockdown. A, Processing of caspases‐8, ‐9, and ‐3 was monitored in A‐375, MeWo,
and Mel‐2a by Western blotting at 72 hours after starting siMcl‐1 or scrambled control siRNA (OffT) transfection and at 24 hours of TRAIL
treatment. Equal protein amounts (30 µg) were loaded as proven by Ponceau staining and GAPDH, used as a loading control. Molecular weights
(in kDa) determined by a protein standard, are given on the right side. Some variations seen here for the GAPDH signals may result from
technical challenges in Western blotting. But Western blots of two independent series of protein extracts revealed highly comparable results.
The caspase‐8 blot was cut to show the different protein fragments. B, Mitochondrial membrane potential (MMP) in response to Mcl‐1
knockdown and TRAIL treatment was determined by TMRM+ staining in A‐375, MeWo, and Mel‐2a at 72 hours after transfection and at
24 hours after TRAIL treatment. C and D, Bax and Bak activation was determined by staining with Bax‐NT (N‐terminus) and Bak‐NT antibodies,
at 60 hours after transfection and at 12 hours after starting TRAIL treatment. B‐D, At least two independent experiments, each one with
triplicates, revealed highly comparable results; mean values and SDs of a representative experiment are shown. Statistical significance was
determined by ANOVA test (two‐way, multiple comparisons) using all individual values (at least six); it is indicated for siMcl‐1 treatment vs
controls or for combination treatment vs siMcl‐1 alone (*P < .05). Examples of treated cells vs controls are given below the bar charts (overlays),
and cell populations with low MMP or activated Bax/Bak (#) are indicated. ANOVA, analysis of variance; Mcl, myeloid cell leukemia; SD,
standard deviation; siRNA, small interfering RNA; TRAIL, TNF‐related apoptosis‐inducing ligand
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Limiting efficiency of BH3 mimetics in melanoma cells has raised
the question about their general applicability for melanoma. We thus
investigated further strategies for posttranscriptional Mcl‐1 control.
miRNAs can efficiently regulate gene expression. Due to the small
size, they allow an efficient packaging in viral vectors, which may be
used in gene‐based therapy.65 Both miR‐339‐3p and miR‐193b have
been shown to suppress melanoma cell proliferation and/or invasion,
which was associated with Mcl‐1 downregulation.32,33 They were
used in the present study to restrict Mcl‐1 expression in MeWo.
Whereas miR‐339‐3p was less effective in combination with TRAIL,
the combination of miR‐193b and TRAIL resulted in significant loss of
cell viability and increased apoptosis. In parallel with the siMcl‐1
approach, strong Bax and Bak activation was observed, indicating the
activation of intrinsic apoptotic pathways.
In conclusion, tumor cells can be targeted by direct apoptosis
agonists, for example, by TRAIL, as well as by inhibition of
F IGURE 5 Use of miRNAs and S63845 to overcome TRAIL resistance. A, MeWo cells were treated with 5 µM S63845 and TRAIL
(100 ng/mL, light grey bars, following at 48 hours by determination of apoptosis (PI assay) and cell survival (calcein assay). Bax and Bak
activation was quantified by NT antibodies at 12 hours posttreatment. B‐E, MeWo cells were transfected with scrambled siRNA (OffT),
siMcl‐1, miR‐193b, miR‐339‐3p, or were nontransfected (Ctr). In addition, they were treated with TRAIL at 48 hours posttransfection
(100 ng/mL, light grey bars). TRAIL treatment was for 48 hours for determination of apoptosis (B) and cell survival (C), whereas for Bax
(D) and Bak activation assays (E), TRAIL treatment was for only 12 hours. A‐E, At least two independent experiments were performed,
each one with at least duplicates; data are expressed as means ±SDs of all individual values (n = 4). Statistical significance of single‐
treated cells (w/o TRAIL, dark grey bars) is indicated vs nontreated controls, whereas the statistical significance of combination
treatments (TRAIL+, light grey bars) is indicated vs TRAIL treatment alone (*P < .05). SD, standard deviation; siRNA, small interfering
RNA; TRAIL, TNF‐related apoptosis‐inducing ligand
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antiapoptotic mechanisms. The present study demonstrates the only
limited value of single treatments, while the combination of TRAIL
and Mcl‐1 targeting revealed high efficiency in 2D cultures of mel-
anoma cells. The principle strategy of combining apoptosis agonists
and the targeting of antiapoptotic pathways appears generally pro-
mising in cancer therapy. Also, further combinations with MAPK in-
hibitors may be considered, in particular also due to crosstalks
between MAPKs and Bcl‐2 proteins. Thus, MAPK activation results in
downregulation of the proapoptotic protein Bim, which serves as an
important antagonist of Mcl‐1.66,67
Of course, 2D cell cultures represent only a highly simplified
model of cancer. The situation may improve when more complex
models as 3D cultures or animals are used. Indeed, we have shown
previously the antitumor effects of TRAIL in melanoma nude mouse
models, when TRAIL was expressed by a replication‐competent
adenoviral vector.68 As other drugs, BH3 mimetics may reveal
varying efficacy in different tumor models as 2D, 3D, and in vivo, as
previously shown.56 Nevertheless, BH3 mimetics are presently pro-
mising enough for their clinical testing in patients with different
tumors.60‐62 Thus, it appears conceivable that the good combination
effects we saw here in a basic melanoma model may be finally
translated into a clinical situation. Thus, after possibly further testing
the particular effectors identified here in animal models, pharmaco-
logical use of TRAIL and S63845 or gene therapeutic use of
miR‐193b may be considered for melanoma therapy.
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